Ilana represents major corporations, including pharmaceutical companies, financial institutions, insurance companies, and high-profile individuals in complex litigation matters. She practices in general litigation before state and federal courts—including coordinated multidistrict litigation—and represents her clients in matters ranging from complex multi-jurisdictional disputes to civil securities fraud actions and boundary-pushing product liability cases. Ilana also represents individuals and corporations in connection with regulatory investigations and related civil proceedings. Her litigation experience includes the following.
Class actions and mass arbitrations. Defends businesses in class action litigation in federal and state courts around the country, with a focus on strategy issues, multidistrict litigation, and critical motions seeking the dismissal of class actions or opposing class certifications. Also represents companies in threatened and filed mass arbitrations, in which plaintiffs’ counsel seek to represent large numbers of consumers or workers in similar serial arbitrations.
Product liability litigation. Represents pharmaceutical, chemical, tobacco, and other types of manufacturers in product liability disputes across multiple jurisdictions, including suits premised on a state’s novel interpretations of the Drug Dealer Liability Act.
Complex civil litigation. Represents local, national and global corporate clients in federal and state courts in a variety of civil actions, including commercial actions, contract disputes, class actions, breach of fiduciary duty claims, and antitrust matters. Also represents corporations and individual officers and directors in federal securities class actions and shareholder derivative suits, and counsels clients and boards of directors in connection with securities law issues.
Trial practice. Develops strategy for complex trial litigation, and has handled many aspects of trial preparation, including dispositive motions, mock jury panels, and witness (fact and expert) preparation.
Appellate practice. Litigates appeals and develops legal strategy at the trial level to ensure appellate preservation, including arguing motions in limine and evidentiary issues, proposed jury instructions and verdict forms, and directed-verdict motions.
Ilana earned her J.D. from The George Washington University Law School, where she was executive editor of The Federal Circuit Bar Journal. She then served as a law clerk to the Honorable Michael M. Baylson of the U.S. District Court for the Eastern District of Pennsylvania. Before joining Shook, Ilana was an associate in the Manhattan office of an Am Law 100 firm.
Representative Matters
Member of trial team in client’s first case to proceed to trial in Portland, Oregon state court whose product was alleged to have caused plaintiff's terminal cancer. After a two-week trial, plaintiffs' counsel asked the jury to award plaintiff $20 million in compensatory damages, his wife $2 million in loss of consortium damages and $140 million in punitive damages. The jury awarded plaintiff $750,000, nothing to his wife and no punitive damages.
Defended CMBS broker-dealer in SEC enforcement action that led to full defense verdict after jury trial.
Defended pharmaceutical company in opioid litigation. Developed and coordinated overall litigation strategy, including working with in-house counsel and business units to develop positions and ensure continuity across opioid-related proceedings filed in various state and federal jurisdictions across the United States.
Defended insurance company against putative class-action claims for breach of contract related to COVID-19, including management of multidistrict litigation coordinated in the Southern District of New York.
Defended major technology company in breach of contract and fraud action in federal court. Obtained full defense verdict after jury trial.
Defended telecommunications company in securities class action and related shareholder derivative actions.
Media Coverage
Jury Clears Ex-Nomura Trader, Rejects SEC No-Lying Theory, Law360, May 6, 2022.